Apoptosis signal-regulating kinase inhibitors and uses thereof
Described herein are ASK1 inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of blood disease, autoimmune disorders, pulmonary disorders, hypertension, inflammatory diseases, fibrotic diseases, diabetes, diabetic nephropathy, renal diseases, respiratory diseases, cardiovascular diseases, acute lung injuries, acute or chronic liver diseases, and neurodegenerative diseases.
1. A compound of Formula (Ia), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof:
wherein:
L is
each R 7a and R 7b is independently hydrogen, halogen, —CN, —OR a , —SR a , —S(═O)R b , —NO 2 , —NR c R d , —S(═O) 2 R d , —NR a S(═O) 2 R d , —S(═O) 2 NR c R d , —C(═O)R b , —OC(═O)R b , —CO 2 R a , —OCO 2 R a , —C(═O)NR c R d , —OC(═O)NR c R d , —NR a C(═O)NR c R d , —NR a C(═O)R b , —NR a C(═O)OR a , optionally substituted C 1 -C 6 alkyl, optionally substituted C 2 -C 6 alkenyl, optionally substituted C 2 -C 6 alkynyl, optionally substituted C 1 -C 6 heteroalkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl;
or R 7a and R 7b on the same carbon atom are taken together to form an oxo;
or two R 7a are taken together to form an optionally substituted cycloalkyl;
each Y is independently —NR 7c —, —O—, —S—, —S(═O)—, or —S(═O) 2 —;
each R 7c is independently hydrogen, —S(═O)R b , —S(═O) 2 R d , —S(═O) 2 NR c R d , —C(═O)R b , —CO 2 R a —C(═O)NR c R d , optionally substituted C 1 -C 6 alkyl, optionally substituted C 2 -C 6 alkenyl, optionally substituted C 2 -C 6 alkynyl, optionally substituted C 1 -C 6 heteroalkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl;
c is 2-8;
X 1 is N or CR 1 ;
X 2 is N or CR 2 ;
X 3 is N or CR 3 ;
each R 1 , R 2 , and R 3 is independently hydrogen, halogen, —CN, —OR a , —SR a , —S(═O)R b , —NO 2 , —NR c R d , —S(═O) 2 R d , —NR a S(═O) 2 R d , —S(═O) 2 NR c R d , —C(═O)R b , —OC(═O)R b , —CO 2 R a , —OCO 2 R a , —C(═O)NR c R d , —OC(═O)NR c R d , —NR a C(═O)NR c R d , —NR a C(═O)R b , —NR a C(═O)OR a , optionally substituted C 1 -C 6 alkyl, optionally substituted C 2 -C 6 alkenyl, optionally substituted C 2 -C 6 alkynyl, optionally substituted C 1 -C 6 heteroalkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl;
each R 4 is independently hydrogen, halogen, —CN, —OR a , —SR a , —S(═O)R b , —NO 2 , —NR c R d , —S(═O) 2 R d , —NR a S(═O) 2 R d , —S(═O) 2 NR c R d , —C(═O)R b , —OC(═O)R b , —CO 2 R a , —OCO 2 R a , —C(═O)NR c R d , —OC(═O)NR c R d , —NR a C(═O)NR c R d , —NR a C(═O)R b , —NR a C(═O)OR a , optionally substituted C 1 -C 6 alkyl, optionally substituted C 2 -C 6 alkenyl, optionally substituted C 2 -C 6 alkynyl, optionally substituted C 1 -C 6 heteroalkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl;
or two R 4 are taken together to form an optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl;
R 5 is hydrogen, —S(═O)R b , —S(═O) 2 R d , —S(═O) 2 NR c R d , —C(═O)R b , —OCO 2 R a , —C(═O)NR c R d , optionally substituted C 1 -C 6 alkyl, optionally substituted C 2 -C 6 alkenyl, optionally substituted C 2 -C 6 alkynyl, optionally substituted C 1 -C 6 heteroalkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl;
each R 6 is independently hydrogen, halogen, —CN, —OR a , —SR a , —S(═O)R b , —NO 2 , —NR c R d , —S(═O) 2 R d , —NR a S(═O) 2 R d , —S(═O) 2 NR c R d , —C(═O)R b , —OC(═O)R b , —CO 2 R a , —OCO 2 R a , —C(═O)NR c R d , —OC(═O)NR c R d , —NR a C(═O)NR c R d , —NR a C(═O)R b , —NR a C(═O)OR a , optionally substituted C 1 -C 6 alkyl, optionally substituted C 2 -C 6 alkenyl, optionally substituted C 2 -C 6 alkynyl, optionally substituted C 1 -C 6 heteroalkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl;
R a is hydrogen, optionally substituted C 1 -C 6 alkyl, optionally substituted C 2 -C 6 alkenyl, optionally substituted C 2 -C 6 alkynyl, optionally substituted C 1 -C 6 heteroalkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl;
R b is optionally substituted C 1 -C 6 alkyl, optionally substituted C 2 -C 6 alkenyl, optionally substituted C 2 -C 6 alkynyl, optionally substituted C 1 -C 6 heteroalkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl;
each R c and R d is independently hydrogen, optionally substituted C 1 -C 6 alkyl, optionally substituted C 2 -C 6 alkenyl, optionally substituted C 2 -C 6 alkynyl, optionally substituted C 1 -C 6 heteroalkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl;
or R c and R d , together with the nitrogen atom to which they are attached, form an optionally substituted heterocycloalkyl or optionally substituted heteroaryl;
s is 1-3; and
t is 1-3.
2. The compound of claim 1 , wherein the compound of Formula (Ia) is of Formula (Ib), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof:
3. The compound of claim 1 , or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein:
each R 4 is independently hydrogen, halogen, —CN, —OR a , —NR c R d , —CO 2 R a , —C(═O)NR c R d , optionally substituted C 1 -C 6 alkyl, optionally substituted C 2 -C 6 alkynyl, optionally substituted C 1 -C 6 heteroalkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl, or two R 4 are taken together to form an optionally substituted heterocycloalkyl.
4. The compound of claim 1 , or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein:
each R 4 is independently hydrogen, halogen, —CN, —OR a , optionally substituted C 1 -C 6 alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl.
5. The compound of claim 1 , or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein:
s is 1 or 2.
6. The compound of claim 1 , or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein:
each R 6 is hydrogen.
7. The compound of claim 1 , or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein:
R 5 is hydrogen or optionally substituted C 1 -C 6 alkyl.
8. The compound of claim 1 , or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein:
each R 7a and R 7a is independently hydrogen, halogen, or optionally substituted C 1 -C 6 alkyl;
or R 7a and R 7b on the same carbon atom are taken together to form an oxo;
or two R 7a are taken together to form an optionally substituted cycloalkyl;
Y is —NR 7c —, —O—, —S—, —S(═O)—, or —S(═O) 2 —;
R 7c is hydrogen or optionally substituted C 1 -C 6 alkyl,
c is 2-4.
9. The compound of claim 8 , or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein:
Y is —O—.
10. The compound of claim 8 , or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein:
each R 7a and R 7b is independently hydrogen, halogen, or optionally substituted C 1 -C 6 alkyl or two R 7a are taken together to form an optionally substituted cycloalkyl.
11. The compound of claim 8 , or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein:
each R 7a and R 7b is hydrogen.
12. The compound of claim 1 , or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein:
L is
13. The compound of claim 1 selected from the group consisting of:
or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof.
14. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, and a pharmaceutically acceptable excipient.
15. A method for treating a disease in a mammal comprising administering to the mammal a therapeutically effective amount of the compound of claim 1 , or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof.
16. The method of claim 15 , wherein the disease is selected from the group consisting of a blood disease, an autoimmune disorder, a pulmonary disorder, hypertension, an inflammatory disease, a fibrotic disease, diabetes, diabetic nephropathy, a renal disease, a respiratory disease, a cardiovascular disease, acute lung injury, acute or chronic liver disease, and a neurodegenerative disease.